Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL. Harris RR, et al. Among authors: marsh k. J Pharmacol Exp Ther. 2004 Dec;311(3):904-12. doi: 10.1124/jpet.104.070052. Epub 2004 Jul 26. J Pharmacol Exp Ther. 2004. PMID: 15277581
A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. Honore P, et al. Among authors: marsh k. J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85. doi: 10.1124/jpet.106.111559. Epub 2006 Sep 18. J Pharmacol Exp Ther. 2006. PMID: 16982702
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Fox GB, et al. Among authors: marsh k. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. doi: 10.1124/jpet.104.078402. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608077
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee CH, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. Honore P, et al. Among authors: marsh k. J Pharmacol Exp Ther. 2005 Jul;314(1):410-21. doi: 10.1124/jpet.105.083915. Epub 2005 Apr 18. J Pharmacol Exp Ther. 2005. PMID: 15837818
Rapamycin analogs with reduced systemic exposure.
Wagner R, Mollison KW, Liu L, Henry CL, Rosenberg TA, Bamaung N, Tu N, Wiedeman PE, Or Y, Luly JR, Lane BC, Trevillyan J, Chen YW, Fey T, Hsieh G, Marsh K, Nuss M, Jacobson PB, Wilcox D, Carlson RP, Carter GW, Djuric SW. Wagner R, et al. Among authors: marsh k. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. doi: 10.1016/j.bmcl.2005.06.106. Epub 2005 Sep 26. Bioorg Med Chem Lett. 2005. PMID: 16185865
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ. Jacobson PB, et al. Among authors: marsh k. J Pharmacol Exp Ther. 2005 Jul;314(1):191-200. doi: 10.1124/jpet.104.081257. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784656
Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Fryer RM, Rakestraw PA, Preusser LC, Brune ME, Carroll WA, Buckner SA, Shieh CC, King LL, Marsh KC, Gopalakrishnan M, Cox BF, Reinhart GA. Fryer RM, et al. J Cardiovasc Pharmacol. 2005 Aug;46(2):232-40. doi: 10.1097/01.fjc.0000171755.28317.85. J Cardiovasc Pharmacol. 2005. PMID: 16044036
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Fryer RM, Preusser LC, Calzadilla SV, Hu Y, Xu H, Marsh KC, Cox BF, Lin CT, Gopalakrishnan M, Reinhart GA. Fryer RM, et al. J Cardiovasc Pharmacol. 2004 Aug;44(2):137-47. doi: 10.1097/00005344-200408000-00001. J Cardiovasc Pharmacol. 2004. PMID: 15243293
1,193 results